BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. It leverages its proprietary DPX™ immune-educating delivery technology platform alongside its Haptenix© neoantigen tumor cell construct platform to create vaccines that stimulate enhanced T-cell responses. Key programs include maveropepimut-S, in Phase IIb trials for relapsed-refractory diffuse large B-cell lymphoma and platinum-resistant ovarian cancer, and BVX-0918, a personalized vaccine entering Phase I for late-stage ovarian cancer. BioVaxys capitalizes on tumor immunology expertise and predictive algorithms to identify targetable tumor antigens. Its technology platforms harness haptenization—a method enhancing immune recognition of tumor and viral proteins—underpinned by exclusive patents and collaboration with leading institutions. Founded in 2020, BioVaxys plays a significant role in advancing precision medicine within immunotherapy, reflecting the growing global demand for innovative therapies in oncology and infectious disease management.